Proprietary tumor antigen A+ (PTA-A+)

Proprietary tumor antigen A+ is a specific tumor-associated antigen utilized as a therapeutic target in advanced cancer immunotherapy platforms, most notably within BioNTech's FixVac (Fixed Antigen Vaccine) pipeline. It is typically part of a multi-antigen mRNA vaccine formulation designed to trigger a robust and coordinated immune response against malignant cells expressing the antigen. In clinical applications, such as the BNT112 program for prostate cancer, this antigen is selected based on its high prevalence and restricted expression in tumor tissues compared to healthy cells. By delivering the genetic blueprint of Proprietary tumor antigen A+ via lipid nanoparticles, the therapy induces the patient's own immune system to recognize and eliminate cancer cells. This approach aims to overcome tumor immune evasion and provide a durable therapeutic effect in patients with advanced malignancies.

Other names

Proprietary tumor antigen AAntigen A+Tumor-associated antigen A+

Induction of antigen-specific T-cell responses via mRNA-based vaccination